These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17661735)

  • 41. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial.
    Espinola-Klein C; Weisser G; Jagodzinski A; Savvidis S; Warnholtz A; Ostad MA; Gori T; Munzel T
    Hypertension; 2011 Aug; 58(2):148-54. PubMed ID: 21646599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
    AlHabeeb W; Mrabeti S; Abdelsalam AAI
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):959-971. PubMed ID: 34106365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nebivolol: a review of its clinical and pharmacological characteristics.
    Gielen W; Cleophas TJ; Agrawal R
    Int J Clin Pharmacol Ther; 2006 Aug; 44(8):344-57. PubMed ID: 16961165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.
    Giles TD; Khan BV; Lato J; Brener L; Ma Y; Lukic T
    J Clin Hypertens (Greenwich); 2013 Sep; 15(9):687-93. PubMed ID: 24034663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prospective follow-up of nebivolol in the treatment of arterial hypertension].
    Despotović N; Matić-Cvetković D; Ivanović B
    Srp Arh Celok Lek; 2012; 140(7-8):425-30. PubMed ID: 23092025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial.
    Van Nueten L; Lacourcière Y; Vyssoulis G; Korlipara K; Marcadet DM; Dupont AG; Robertson JI
    Am J Ther; 1998 Jul; 5(4):237-43. PubMed ID: 10099065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol.
    Giles TD
    Am J Med; 2010 Jul; 123(7 Suppl 1):S16-20. PubMed ID: 20609694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
    Rizos E; Bairaktari E; Kostoula A; Hasiotis G; Achimastos A; Ganotakis E; Elisaf M; Mikhailidis DP
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):127-34. PubMed ID: 12808486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.
    Tarighi B; Kurum T; Demir M; Azcan SN
    Can J Cardiol; 2007 Jun; 23(8):651-5. PubMed ID: 17593991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arterial stiffness, hypertension, and rational use of nebivolol.
    Agabiti-Rosei E; Porteri E; Rizzoni D
    Vasc Health Risk Manag; 2009; 5(1):353-60. PubMed ID: 19475771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design.
    Shibata MC; Flather MD; Böhm M; Borbola J; Cohen-Solal A; Dumitrascu D; Ferrari R; Lechat P; Parkhomenko A; Soler-Soler J; Tavazzi L; Toman J; Van Veldhuisen DJ; Coats AJ; Poole-Wilson P;
    Int J Cardiol; 2002 Nov; 86(1):77-85. PubMed ID: 12243852
    [No Abstract]   [Full Text] [Related]  

  • 56. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
    Tzemos N; Lim PO; MacDonald TM
    Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension.
    Sander GE; Giles TD
    Expert Opin Pharmacother; 2015 Apr; 16(5):763-70. PubMed ID: 25747524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure.
    de Groot AA; Mathy MJ; van Zwieten PA; Peters SL
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):56-60. PubMed ID: 17666916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Nebivolol: a beta blocker with vasodilator properties].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(15):631-3. PubMed ID: 10804847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacology of nebivolol.
    Mangrella M; Rossi F; Fici F; Rossi F
    Pharmacol Res; 1998 Dec; 38(6):419-31. PubMed ID: 9990650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.